A study to determine patient specific markers to customize cancer therapy.
- Conditions
- Health Condition 1: null- Newly Diagnosed or recurrent Leukemia
- Registration Number
- CTRI/2014/03/004446
- Lead Sponsor
- Mazumdar Shaw Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 14
Newly Diagnosed and recurrent Leukemia
- Willing to provide informed consent
-Patients with the history of heart diseases. e.g., NYHA Functional Class III or IV heart failure, Myocardial Infarction within 6 months , ventricular tachyarrhythmias requiringongoing treatment, or unstable angina, or heart rhythm disorder
-Patients with the history of psychological problems that would precludeparticipation in the study(like confusion, hallucination, loss of balance, change in the way you walk or talk, decreased).
-Patients for whom, in the opinion of the investigator, their general status would not permit the administration of chemotherapy
-Inability of the patient or Legally Acceptable Representative to give the informed consent.
-Patients who are participating in another clinical trial currently.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Assess Marrow concentration of blast cells.Timepoint: -At baseline <br/ ><br>-At 6 weeks follow-up.
- Secondary Outcome Measures
Name Time Method To identify patient-specific adjuvants and/or alternative drugs in leukemic patients.Timepoint: After Pecaso Analysis